This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmitz, F.-J.
Right arrow Articles by C. Fluit, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmitz, F.-J.
Right arrow Articles by C. Fluit, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2002, p. 934-935, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.934-935.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

In Vitro Activities of Novel Des-Fluoro(6) Quinolone BMS-284756 against Mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus Selected with Different Quinolones


arrow
LETTER
 
BMS-284756 (T-3811) is a novel quinolone that lacks a fluorine at the C-6 position. BMS-284756 has a broad spectrum of antibacterial activity (3, 7). The purpose of the present study was (i) to analyze the in vitro activity of the novel quinolone against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with marketed quinolones and (ii) to investigate whether this compound is a substrate for efflux pumps.

In order to analyze these therapeutically important aspects, we repeatedly exposed six clinical strains of each species to ciprofloxacin, gatifloxacin, moxifloxacin, and BMS-284756, as described previously for several other quinolones (1).

MICs were determined using microdilution methodology according to NCCLS guidelines (5). MIC determinations for BMS-284756 were conducted in the presence and absence of reserpine (20µg/ml; tests were repeated three times) for all of the original isolates (n = 18) as well as for all of the selected mutants (n = 72) (1, 2).

In addition, isolates were analyzed before and after transfers for mutations in the quinolone-resistance determining regions of parC or grlA and gyrA (4, 6, 8).

The MIC results from subculturing as well as the alterations in the quinolone resistance-determining regions are listed in Table 1,


View this table:
[in this window]
[in a new window]
  		TABLE 1. Resistance selection results for six Streptococcus pneumoniae, six Streptococcus pyogenes, and six Staphylococcus aureus isolatesa

BMS-284756 (range, 0.004 to 0.06 µg/ml) exhibited the best in vitro activities against all 18 original isolates, followed by moxifloxacin (range, 0.03 to 0.25 µg/ml) and gatifloxacin (range, 0.06 to 0.5 µg/ml). Ciprofloxacin (range, 0.125 to 2 µg/ml) showed the lowest in vitro activities. Furthermore, BMS-284756 (range, 0.015 to 8 µg/ml) exhibited the best in vitro activities against all 72 selected mutants, followed by moxifloxacin (range, 0.06 to 64 µg/ml), gatifloxacin (range, 0.06 to 128 µg/ml), and ciprofloxacin (range, 0.25 to 256 µg/ml) (Table 1).

None of the original 18 strains and none of the 72 selected mutants displayed lower MICs for BMS-284756 in the presence of reserpine. These results illustrate that the novel quinolone is not a good substrate for efflux pumps.

Based on the results presented, i.e., two- to ninefold increases in MICs after passages in BMS-284756-containing medium, the new quinolone seems to have the same potential for resistance development as that of the C-8 methoxy quinolones gatifloxacin and moxifloxacin. Alterations in ParC (S79Y or S79F) and GyrA (S81F) contributed to the resistance seen in S. pneumoniae mutants selected by BMS-284756. In Streptococcus pyogenes mutants, alterations in ParC (S79A and S79F) and GyrA (S81Y or E85G) were found. In addition, classical alterations in GrlA (S80Y, S80F, or E84K) and GyrA (S84L) contributed to the resistance in S. aureus mutants selected by BMS-284756. These classical alterations are identical to those observed in isolates selected by other quinolones (4, 6, 8).

In summary, the new quinolone BMS-84756 has good in vitro activity against wild-type isolates and selected mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. The novel quinolone is not a good substrate for efflux. BMS-84756 seems to have the same potential for resistance development as that of the C-8 methoxy quinolones gatifloxacin and moxifloxacin.


arrow
REFERENCES
 
    1
  1. Boos, M., S. Mayer, A. Fischer, K. Köhrer, S. Scheuring, P. Heisig, J. Verhoef, A. C. Fluit, and F.-J. Schmitz. 2001. In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob. Agents Chemother. 45:938-942.[Abstract/Free Full Text]
    2. 2
  2. Davies, T. A., L. M. Kelly, G. A. Pankuch, K. L. Credito, M. R. Jacobs, and P. C. Appelbaum. 2000. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob. Agents Chemother. 44:304-310.[Abstract/Free Full Text]
    3. 3
  3. Fung-Tome, J. C., B. Minassian, B. Kolek, E. Huczko, L. Aleksunes, T. Stickle, T. Washo, E. Gradelski, L. Valera, and D. P. Bonner. 2000. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44:3351-3356.[Abstract/Free Full Text]
    4. 4
  4. Jones, M. E., D. F. Sahm, N. Martin, S. Scheuring, P. Heisig, C. Thornsberry, K. Köhrer, and F.-J. Schmitz. 2000. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different quinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44:462-466[Abstract/Free Full Text]
    5. 5
  5. National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing: eighth informational supplement. NCCLS document M100-S8. National Committee for Clinical Laboratory Standards, Villanova, Pa.
    6. 6
  6. Schmitz, F.-J., M.-E. Jones, B. Hofmann, B. Hansen, S. Scheuring, M. Lückefahr, A. Fluit, J. Verhoef, U. Hadding, H.-P. Heinz, and K. Köhrer. 1998. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob. Agents Chemother. 42:1249-1252[Abstract/Free Full Text]
    7. 7
  7. Takahata, M., J. Mitsuyama, Y. Yamashiro, M. Yonezawa, H. Araki, Y. Todo, S. Minami, Y. Watanabe, and H. Narita. 1999. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob. Agents Chemother. 43:1077-1083.[Abstract/Free Full Text]
    8. 8
  8. Yan, S. S., M. L. Fox, S. M. Holland, F. Stock, V. J. Gill, and D. P. Fedorko. 2000. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance. Antimicrob. Agents Chemother.44:3196-3198.[Abstract/Free Full Text]
Franz-Josef Schmitz*
Mechthild Boos
Susanne Mayer
Karl Köhrer
Sibylle Scheuring
Institute for Medical Microbiology and Virology
University Hospital Düsseldorf
Universitätsstrasse 1, Geb. 22.21
40225 Düsseldorf, Germany

Ad C. Fluit
Eijkman-Winkler Institute for Medical Microbiology
University Medical Center Utrecht
Utrecht, The Netherlands

* Phone and fax: 49-2132-72040
E-mail: schmitfj{at}uni-duesseldorf.de

Antimicrobial Agents and Chemotherapy, March 2002, p. 934-935, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.934-935.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Billal, D. S., Fedorko, D. P., Yan, S. S., Hotomi, M., Fujihara, K., Nelson, N., Yamanaka, N. (2007). In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types. J Antimicrob Chemother 59: 28-34 [Abstract] [Full Text]  
  • Christiansen, K. J., Bell, J. M., Turnidge, J. D., Jones, R. N. (2004). Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001. Antimicrob. Agents Chemother. 48: 2049-2055 [Abstract] [Full Text]  
  • Van Bambeke, F., Glupczynski, Y., Plesiat, P., Pechere, J. C., Tulkens, P. M. (2003). Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother 51: 1055-1065 [Full Text]  
  • Alonso, R., Galimand, M., Courvalin, P. (2002). parC Mutation Conferring Ciprofloxacin Resistance in Streptococcus pyogenes BM4513. Antimicrob. Agents Chemother. 46: 3686-3687 [Full Text]  

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmitz, F.-J.
Right arrow Articles by C. Fluit, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmitz, F.-J.
Right arrow Articles by C. Fluit, A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»